Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,144 Cr.
- Current Price ₹ 350
- High / Low ₹ 582 / 281
- Stock P/E
- Book Value ₹ 47.6
- Dividend Yield 0.00 %
- ROCE -2.14 %
- ROE -4.76 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 7.36 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -10.3% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 498 | 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | 310 | 370 | |
| 586 | 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | 317 | 407 | |
| Operating Profit | -88 | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 | -7 | -37 |
| OPM % | -18% | 10% | 17% | 13% | -4% | -152% | -57% | 0% | -31% | -24% | 4% | -2% | -10% |
| 304 | 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | 17 | 18 | |
| Interest | 148 | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 | 15 | 24 |
| Depreciation | 69 | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 | 20 | 19 |
| Profit before tax | -0 | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 | -26 | -61 |
| Tax % | 0% | 3% | 38% | -14% | 17% | 29% | 13% | 12% | 0% | 40% | 16% | -42% | |
| -0 | -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | -15 | -42 | |
| EPS in Rs | -0.07 | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 | -2.48 | -6.86 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 22% |
| TTM: | -900% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 11% |
| 3 Years: | 41% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | -16% |
| 5 Years: | -10% |
| 3 Years: | -10% |
| Last Year: | -5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 556 | 517 | 518 | 450 | 382 | 412 | 887 | 502 | 409 | 320 | 323 | 308 | 286 |
| 990 | 1,031 | 1,035 | 1,023 | 970 | 689 | 67 | 65 | 84 | 102 | 125 | 228 | 280 | |
| 334 | 325 | 248 | 303 | 316 | 335 | 179 | 217 | 263 | 296 | 300 | 327 | 280 | |
| Total Liabilities | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 851 |
| 1,086 | 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 423 | 416 | 446 | |
| CWIP | 26 | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 97 | 119 | 97 |
| Investments | 394 | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| 380 | 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | 334 | 309 | |
| Total Assets | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 851 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 33 | 4 | |
| -18 | -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -47 | -61 | |
| -38 | -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | 90 | |
| Net Cash Flow | -3 | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 | 33 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 | 25 |
| Inventory Days | 310 | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 | 541 |
| Days Payable | 397 | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 299 | 586 |
| Cash Conversion Cycle | -20 | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -10 | -21 |
| Working Capital Days | -403 | -229 | -80 | -133 | -682 | -49 | 892 | 4 | -63 | -135 | -79 | -141 |
| ROCE % | -9% | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% | 4% | -2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Feb - Newspaper copies of the Extract of Statement of Unaudited Financial Results for quarter and nine months ended 31.12.2025.
- Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31, 2025 11 Feb
-
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31, 2025
11 Feb - Unaudited Q3/9M FY26 results approved; consolidated 9M revenue Rs47,302 L; consolidated 9M loss before tax Rs2,291 L.
-
Details Of Shares Dematerialized During January 2026
Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
6 Feb - No shares dematerialized in January 2026; total 61,101,526 demat shares (NSDL 53,432,223; CDSL 7,669,303).
-
Outcome Of Inspection By National Centre For Public Health And Pharmacy, Hungary At Manufacturing Facility Of Panacea Biotec Pharma Limited At Baddi, Himachal Pradesh
5 Feb - NCPHP revoked Baddi facility GMP certificates after Jan 26–31, 2026 inspection; proposed halt of non-vital EU supplies; EU revenue 0.32%.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix